Thus, MJC13 can inhibit basal, DHT and β-catenin stimulated proliferation in this AR-dependent prostate cancer cell line and MJC13 actions differ from those of flutamide or bicalutamide. The gene discussed is AR; the disease is Familial prostate cancer.